

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Nirogacestat for treating desmoid tumours [ID6453]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

<p>Yes. People who fall under one of the three protected characteristics under the Equality Act 2010: sex, pregnancy and maternity, and age should be considered, because:</p>
--

- | |
|--|
| <ul style="list-style-type: none">• there is a higher incidence of DTs amongst women• of the associated risk of DTs for women in pregnancy• of the relatively younger age profile of people who are diagnosed with DTs |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

<p>The equality issues should be considered by the Committee when making recommendations.</p>

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

<p>The consultation comments response form notes that these equalities issues will be considered by committee</p>

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name):

Date: [xx/xx/year]